Current perspectives on the treatment of patients with chronic myeloid leukemia: An individualized approach to treatment

Elias Jabbour, Jorge Cortes, Francis Giles, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy in CML have resulted in new and revised treatment guidelines or algorithms, which are reviewed here. Methods: Data were identified by searches of MEDLINE, PubMed, and references from relevant articles using the terms "chronic myeloid leukemia, " "imatinib" and "tyrosine kinase inhibitors. " Articles published in English between 1996 and 2006 were included. Results: In this article we review consensus criteria for a therapeutic response and current expectations for CML therapy with imatinib, as well as the evidence supporting these recommendations. In addition, novel approaches to CML treatment are considered in light of the availability of second-generation tyrosine kinase inhibitors. Conclusion: With the advent of novel agents capable of treating imatinib-resistant or imatinib-intolerant CML, it should be possible in the future to further refine treatment algorithms.

Original languageEnglish (US)
Pages (from-to)357-365
Number of pages9
JournalCancer Journal
Volume13
Issue number6
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
PubMed
MEDLINE
Imatinib Mesylate
Guidelines

Keywords

  • Chronic myeloid leukemia
  • Imatinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Current perspectives on the treatment of patients with chronic myeloid leukemia : An individualized approach to treatment. / Jabbour, Elias; Cortes, Jorge; Giles, Francis; Kantarjian, Hagop.

In: Cancer Journal, Vol. 13, No. 6, 01.11.2007, p. 357-365.

Research output: Contribution to journalArticle

@article{0a2e8a7635004561a89b504267b3a91f,
title = "Current perspectives on the treatment of patients with chronic myeloid leukemia: An individualized approach to treatment",
abstract = "Purpose: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy in CML have resulted in new and revised treatment guidelines or algorithms, which are reviewed here. Methods: Data were identified by searches of MEDLINE, PubMed, and references from relevant articles using the terms {"}chronic myeloid leukemia, {"} {"}imatinib{"} and {"}tyrosine kinase inhibitors. {"} Articles published in English between 1996 and 2006 were included. Results: In this article we review consensus criteria for a therapeutic response and current expectations for CML therapy with imatinib, as well as the evidence supporting these recommendations. In addition, novel approaches to CML treatment are considered in light of the availability of second-generation tyrosine kinase inhibitors. Conclusion: With the advent of novel agents capable of treating imatinib-resistant or imatinib-intolerant CML, it should be possible in the future to further refine treatment algorithms.",
keywords = "Chronic myeloid leukemia, Imatinib, Tyrosine kinase inhibitors",
author = "Elias Jabbour and Jorge Cortes and Francis Giles and Hagop Kantarjian",
year = "2007",
month = "11",
day = "1",
doi = "10.1097/PPO.0b013e31815b0df7",
language = "English (US)",
volume = "13",
pages = "357--365",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",

}

TY - JOUR

T1 - Current perspectives on the treatment of patients with chronic myeloid leukemia

T2 - An individualized approach to treatment

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Giles, Francis

AU - Kantarjian, Hagop

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Purpose: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy in CML have resulted in new and revised treatment guidelines or algorithms, which are reviewed here. Methods: Data were identified by searches of MEDLINE, PubMed, and references from relevant articles using the terms "chronic myeloid leukemia, " "imatinib" and "tyrosine kinase inhibitors. " Articles published in English between 1996 and 2006 were included. Results: In this article we review consensus criteria for a therapeutic response and current expectations for CML therapy with imatinib, as well as the evidence supporting these recommendations. In addition, novel approaches to CML treatment are considered in light of the availability of second-generation tyrosine kinase inhibitors. Conclusion: With the advent of novel agents capable of treating imatinib-resistant or imatinib-intolerant CML, it should be possible in the future to further refine treatment algorithms.

AB - Purpose: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy in CML have resulted in new and revised treatment guidelines or algorithms, which are reviewed here. Methods: Data were identified by searches of MEDLINE, PubMed, and references from relevant articles using the terms "chronic myeloid leukemia, " "imatinib" and "tyrosine kinase inhibitors. " Articles published in English between 1996 and 2006 were included. Results: In this article we review consensus criteria for a therapeutic response and current expectations for CML therapy with imatinib, as well as the evidence supporting these recommendations. In addition, novel approaches to CML treatment are considered in light of the availability of second-generation tyrosine kinase inhibitors. Conclusion: With the advent of novel agents capable of treating imatinib-resistant or imatinib-intolerant CML, it should be possible in the future to further refine treatment algorithms.

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=39749197458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749197458&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31815b0df7

DO - 10.1097/PPO.0b013e31815b0df7

M3 - Article

C2 - 18032972

AN - SCOPUS:39749197458

VL - 13

SP - 357

EP - 365

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 6

ER -